Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Ute Schniegler-Mattox"'
Autor:
Thomas Müller, Carolin Tasser, Michael Tesar, Ivica Fucek, Ute Schniegler-Mattox, Joachim Koch, Kristina Ellwanger
Publikováno v:
mAbs, Vol 15, Iss 1 (2023)
ABSTRACTA challenge when developing therapeutic antibodies is the identification of candidates with favorable pharmacokinetics (PK) early in development. A key determinant of immunoglobulin (IgG) serum half‑life in vivo is the efficiency of pH-depe
Externí odkaz:
https://doaj.org/article/021122a57bc94ae89399b99bab6970be
Autor:
Susanne Wingert, Uwe Reusch, Stefan Knackmuss, Michael Kluge, Michael Damrat, Jens Pahl, Ute Schniegler-Mattox, Thomas Mueller, Ivica Fucek, Kristina Ellwanger, Michael Tesar, Torsten Haneke, Joachim Koch, Martin Treder, Wolfgang Fischer, Erich Rajkovic
Publikováno v:
mAbs, Vol 13, Iss 1 (2021)
Epidermal growth factor receptor (EGFR)-targeted cancer therapy such as anti-EGFR monoclonal antibodies and tyrosine kinase inhibitors have demonstrated clinical efficacy. However, there remains a medical need addressing limitations of these therapie
Externí odkaz:
https://doaj.org/article/4d63d162888a47209f9f61da3778fcae
Autor:
Uwe Reusch, Kristina Ellwanger, Ivica Fucek, Thomas Müller, Ute Schniegler-Mattox, Joachim Koch, Michael Tesar
Publikováno v:
Antibodies, Vol 11, Iss 1, p 12 (2022)
Innate cell engager (ICE®) constructs are bispecific tetravalent antibodies targeting specific tumor antigens and simultaneously engaging natural killer (NK) cell and macrophage receptors for the destruction of tumor cells. Pre-complexing of ICE® c
Externí odkaz:
https://doaj.org/article/c2ab650ca3c04175a6acf0e1b84c5100
Autor:
Martin Treder, Michael Damrat, Torsten Haneke, Stefan Knackmuss, Susanne Wingert, Ute Schniegler-Mattox, Michael Tesar, Thomas Mueller, Michael Kluge, Wolfgang Fischer, Joachim Koch, Kristina Ellwanger, Ivica Fucek, Uwe Reusch, Jens Pahl, Erich Rajkovic
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Epidermal growth factor receptor (EGFR)-targeted cancer therapy such as anti-EGFR monoclonal antibodies and tyrosine kinase inhibitors have demonstrated clinical efficacy. However, there remains a medical need addressing limitations of these therapie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dacbea74272e4ed5763300572357de7e
http://europepmc.org/articles/PMC8331026
http://europepmc.org/articles/PMC8331026
Autor:
Martin Treder, Susanne Wingert, Ivica Fucek, Erich Rajkovic, Thorsten Ross, Thomas Müller, Joachim Koch, Torsten Haneke, Michael Tesar, Ute Schniegler-Mattox, Uwe Reusch, Kristina Ellwanger
Publikováno v:
mAbs
Redirection of immune cells to efficiently eliminate tumor cells holds great promise. Natural killer cells (NK), macrophages, or T cells are specifically engaged with target cells expressing markers after infection or neoplastic transformation, resul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2d55a4472b599feabfabe2867e21001
https://doi.org/10.1080/19420862.2019.1616506
https://doi.org/10.1080/19420862.2019.1616506
Autor:
Thomas Müller, Kristina Ellwanger, Joachim Koch, Michael Tesar, Uwe Reusch, Jens Pahl, Ivica Fucek, Ute Schniegler-Mattox
Publikováno v:
Blood. 138:3992-3992
AFM13 is a bispecific tetravalent innate cell engager (ICE®) with two binding sites for CD16A and CD30 on immune cells and tumor cells, respectively. AFM13 is designed to potently activate anti-tumoral responses of natural killer (NK) cells, through
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8ce6472d19fb1185e1eba5c5d5e69b0
https://doi.org/10.1182/blood-2021-150552
https://doi.org/10.1182/blood-2021-150552
Autor:
Erich Rajkovic, Stefan Knackmuss, Torsten Haneke, Michael Tesar, Wolfgang Fischer, Ute Schniegler-Mattox, Ivica Fucek, Uwe Reusch, Susanne Wingert, Michael Damrat, Kristina Ellwanger, Thomas Mueller, Andras Strassz
Publikováno v:
Cancer Research. 80:5659-5659
The epidermal growth factor receptor (EGFR) is a prime target for cancer therapy across many solid tumor types, including CRC, NSCLC, breast, esophageal cancer, and SCCHN. Binding of EGFR by its ligand EGF induces cell proliferation, a process which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a81727be238a44158cbf09d6ee71f852
https://doi.org/10.1158/1538-7445.am2020-5659
https://doi.org/10.1158/1538-7445.am2020-5659
Autor:
Uwe Reusch, Ute Schniegler-Mattox, Michael Tesar, Anna-Kathrin Otte, Ivica Fucek, Stefan Knackmuss, Thomas Valerius, Susanne Wingert, Matthias Peipp, Kristina Ellwanger, Katja Klausz, Natalie Schub, Martin Treder, Joachim Koch, Thomas Müller, Erich Rajkovic, Torsten Haneke, Martin Gramatzki, Thorsten Ross
Publikováno v:
Blood. 132:1927-1927
Natural killer (NK) cells are crucial effector cells of the innate immune system capable of rapidly recognizing and eliminating infected, stressed and malignant cells. NK cells are also the prime mediators of antibody-dependent cell-mediated cytotoxi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::29852675bc0bcae05d36a8cabca712e0
https://doi.org/10.1182/blood-2018-99-118970
https://doi.org/10.1182/blood-2018-99-118970
Autor:
Ute Schniegler-Mattox, Stefan Knackmuss, Michael Tesar, Ivica Fucek, Torsten Haneke, Kristina Ellwanger, Michael Kluge, Uwe Reusch, Martin Treder, Thomas Mueller
Publikováno v:
Cancer Research. 78:2786-2786
The epidermal growth factor receptor (EGFR) is a validated target for the treatment of several solid tumor types. Current EGFR-targeting monoclonal antibodies (mAbs) and tyrosine kinase inhibitors function mainly through blocking of signal-transducti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa84d11e62ebd5ca978d8c8128fc9ce6
https://doi.org/10.1158/1538-7445.am2018-2786
https://doi.org/10.1158/1538-7445.am2018-2786
Autor:
Matthias, Mack, Ute, Schniegler-Mattox, Verena, Peters, Georg F, Hoffmann, Michael, Liesert, Wolfgang, Buckel, Johannes, Zschocke
Publikováno v:
The FEBS journal. 273(9)
The metabolic disease 3-methylglutaconic aciduria type I (MGA1) is characterized by an abnormal organic acid profile in which there is excessive urinary excretion of 3-methylglutaconic acid, 3-methylglutaric acid and 3-hydroxyisovaleric acid. Affecte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5b5dfc7f582d0c81b8f94b57b78cbe06
https://pubmed.ncbi.nlm.nih.gov/16640564
https://pubmed.ncbi.nlm.nih.gov/16640564